Trung Huynh
Stock Analyst at UBS
(4.46)
# 278
Out of 4,944 analysts
50
Total ratings
63.64%
Success rate
17.31%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Trung Huynh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Buy | $1,050 → $895 | $660.48 | +35.51% | 9 | Aug 8, 2025 | |
| INSM Insmed | Maintains: Buy | $124 → $133 | $122.82 | +8.29% | 6 | Aug 8, 2025 | |
| AMGN Amgen | Maintains: Neutral | $326 → $317 | $287.08 | +10.42% | 6 | Aug 6, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $560 → $584 | $559.97 | +4.29% | 4 | Jul 11, 2025 | |
| JSPR Jasper Therapeutics | Maintains: Buy | $38 → $33 | $2.97 | +1,011.11% | 2 | May 13, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $44 → $38 | $25.06 | +51.64% | 2 | May 9, 2025 | |
| PFE Pfizer | Maintains: Neutral | $24 → $25 | $25.03 | -0.12% | 6 | Apr 30, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $54 | $47.28 | +14.23% | 5 | Apr 11, 2025 | |
| CABA Cabaletta Bio | Maintains: Buy | $10 → $7 | $1.66 | +322.96% | 2 | Apr 1, 2025 | |
| KYTX Kyverna Therapeutics | Initiates: Buy | $13 | $3.29 | +295.14% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $170 → $175 | $173.73 | +0.73% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $126 | $82.24 | +53.21% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $170 | $200.35 | -15.15% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $10.65 | - | 1 | Mar 23, 2021 |
Eli Lilly and Company
Aug 8, 2025
Maintains: Buy
Price Target: $1,050 → $895
Current: $660.48
Upside: +35.51%
Insmed
Aug 8, 2025
Maintains: Buy
Price Target: $124 → $133
Current: $122.82
Upside: +8.29%
Amgen
Aug 6, 2025
Maintains: Neutral
Price Target: $326 → $317
Current: $287.08
Upside: +10.42%
Regeneron Pharmaceuticals
Jul 11, 2025
Maintains: Neutral
Price Target: $560 → $584
Current: $559.97
Upside: +4.29%
Jasper Therapeutics
May 13, 2025
Maintains: Buy
Price Target: $38 → $33
Current: $2.97
Upside: +1,011.11%
Celldex Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $44 → $38
Current: $25.06
Upside: +51.64%
Pfizer
Apr 30, 2025
Maintains: Neutral
Price Target: $24 → $25
Current: $25.03
Upside: -0.12%
Bristol-Myers Squibb Company
Apr 11, 2025
Maintains: Neutral
Price Target: $60 → $54
Current: $47.28
Upside: +14.23%
Cabaletta Bio
Apr 1, 2025
Maintains: Buy
Price Target: $10 → $7
Current: $1.66
Upside: +322.96%
Kyverna Therapeutics
Oct 10, 2024
Initiates: Buy
Price Target: $13
Current: $3.29
Upside: +295.14%
Jul 21, 2023
Maintains: Neutral
Price Target: $170 → $175
Current: $173.73
Upside: +0.73%
Mar 7, 2023
Maintains: Outperform
Price Target: $125 → $126
Current: $82.24
Upside: +53.21%
Nov 18, 2022
Initiates: Outperform
Price Target: $170
Current: $200.35
Upside: -15.15%
Mar 23, 2021
Upgrades: Outperform
Price Target: n/a
Current: $10.65
Upside: -